PubRank

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Clinical Trial ID NCT00450463

PubWeight™ 21.29‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00450463

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 133.74
2 Cancer statistics, 2005. CA Cancer J Clin 2005 25.65
3 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
4 Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997 1.41
5 Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2013 1.16
6 Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011 1.12
7 Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010 1.06
8 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
9 Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2013 0.98
10 Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 0.93
11 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
12 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
13 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
14 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
15 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
16 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
17 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
18 The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer 2010 0.83
19 Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. Oncoimmunology 2014 0.81
20 Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012 0.81
21 DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nanotechnol 2015 0.78
22 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
23 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
24 Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) 2013 0.76
25 Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol 2015 0.76
26 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
Next 100